Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: A randomised, double blind, placebo controlled study

Gut

Volumn 54, Issue 8, 2005, Pages 1169-1173

  Piche, T ^a,b,e   Vanbiervliet, G ^b   Cherikh, F ^b   Antoun, Z ^c   Huet, P M ^b   Gelsi, E ^b   Demarquay, J F ^b   Caroli Bosc, F X ^b   Benzaken, S ^c   Rigault, M C ^b   Renou, C ^b   Rampal, P ^d   Tran, A ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c GLAXOSMITHKLINE   (France)

^d CHR   (France)

^e Centre Hospitalier   (Monaco)

Author keywords

[No Author keywords available]

Indexed keywords

ONDANSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FATIGUE IMPACT SCALE; FEMALE; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; DEPRESSION; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; ONDANSETRON; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 20444448051     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.055251     Document Type: Article

References (34)

1. Kroenke MD, Wood DR, Mangelsdorff AD, et al. Chronic fatigue in primary care. JAMA 1988;260:929-34.
2. Piche T, Gelsi E, Schneider SM, et al. Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut 2002;51:434-9.
3. Gumber SC, Chopra S. Hepatitis C. A multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995;123:615-20.
4. Cauch-Dudek K, Abbey S, Stewart DE, et al. Fatigue in primary biliary cirrhosis. Gut 1998;43:705-10.
5. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
6. Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-11.
7. Fisk JD, Pontrefact A, Ritvo PF, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Can J Neurol Sci 1994;21:9-14.
8. Hassoun Z, Willems B, Deslauriers J, et al. Assessment of fatigue in patients with chronic hepatitis C using the fatigue impact scale (FIS). Dig Dis Sci 2002;47:2674-81.
9. Huet PM, Deslauriers J, Tran A, et al. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 2000;95:760-7.
10. Goldblatt J, Taylor PJS, Lipman T, et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002;122:1235-41.
11. Swain MG, Marie M. Defective corticotropin-releasing hormone mediated neuroendocrine and behavioral responses in cholestatic rats: implications for cholestatic liver disease-related sickness behaviors. Hepatology 1995;22:1560-4.
12. de Lange FP, Kalkman JS, Bleijenberg G, et al. Neural correlates of the chronic fatigue syndrome-an fMRI study. Brain 2004;127:1948-57.
13. Siemionow V, Fang Y, Calabrese L, et al. Altered central nervous system signal during motor performance in chronic fatigue syndrome. Clin Neurophysiol 2004;115:2372-81.
14. Bergasa NV, Jones EA. The pruritus of cholestasis. Potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995;108:1582-8.
15. Forton D, Karayiannis P, Mahmud N, et al. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 2004;78:5170-83.
16. Richardson BP. Serotonin and nociception. Ann N Y Acad Sci 1990;600:511-20.
17. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995;61:33-7.
18. Wilson WM, Maughan RJ. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol 1992;77:921-4.
19. Spath M, Welzel D, Farber L. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists-preliminary results. Scand J Rheumatol Suppl 2000;113:72-7.
20. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet 1999;354:397.
21. Group TFMCS. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
22. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. In: Pichot P, ed. Psychological measurements in psychopharmacology. Basel: Karger, 1974:151-9.
23. Beck AT, Steer R, Garbin M. Psychometric properties of the Beck depression inventory: twenty five years of research. Clin Psychol Rev 1988;8:77-100.
24. Lemperiere T, Lepine JP, Rouillon F, et al. Comparaison de différents instruments d' évaluation de la dépression à l'occasion d'une étude sur l'Athymil 30 mg. Ann Méd Psychol (Paris) 1984;142:1206-12.
25. Collet L, Cottraux J. Inventaire abrégé de la dépression de Beck (13 items). Etude de la validité concurrente avec les échelles de Hamilton et de ralentissement de Widlcher. Encephale 1986;12:77-9.
26. Theal JJ, Toosi MN, Girlan LM, et al. Ondansetron ameliorates fatigue in patients with primary biliary cirrhosis (PBC). Hepatology 2002;36:296A.
27. Figg WD, Dukes GE, Pritchard JF, et al. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol 1996;36:206-15.
28. Khawaja X, Xu J, Liang JJ, et al. Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies. J Neurosci Res 2004;75:451-60.
29. Calapai G, Corica F, Corsonello A, et al. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. J Clin Invest 1999;104:975-82.
30. Dsingh N, Gayowski T, Wagener MM, et al. Vulnerability tto psychological distress and depression in patients with end-stage liver disease due to hepatitis C. Clin Transplant 1997;11:406-11.
31. Jonhson ME, Fisher DG, Fenaughty A, et al. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998;93:785-9.
32. Love AW, Grabsch B, Clarcke DM, et al. Screening for depression in women with metastatic breast cancer: a comparison of the Beck Depression Inventory Short Form and the Hospital Anxiety and Depression Scale. Aust N Z J Psychiatry 2004;38:526-31.
33. Bryson J. Clinical safety of ondansetron. Semin Oncol 1992;19:26-32.
34. Müller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blina cross-over trial. Eur J Gastroenterol Hepatol 1998;10:865-70.